会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • MICRORNA AS A BIOMARKER OF PANCREATIC ISLET BETA-CELL ENGAGEMENT
    • MICRORNA作为PANCREATIC ISLET BETA-CELL参与的生物标记
    • WO2010120578A1
    • 2010-10-21
    • PCT/US2010/029887
    • 2010-04-05
    • MERCK SHARP & DOHME CORP.ZHOU, Yun-PingHOWARD, Andrew, D.SHANG, Jin
    • ZHOU, Yun-PingHOWARD, Andrew, D.SHANG, Jin
    • C12Q1/68
    • C12Q1/686C12Q1/6883C12Q2600/106C12Q2600/136C12Q2525/207C12Q2521/107
    • MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression and which play important roles in many cell types, including as described herein, the pancreatic β-cell. Glucagon like peptide-1 (GLP-1), a hormone released from intestinal L-cells following meal intake, exerts pleiotropic effects on β-cell function including raising intracellular cAMP levels and now represents an important therapy for type 2 diabetes. Expression of miR-132 and miR212 is upregulated by CREB protein in response increased cAMP levels in the cell; therefore, methods for detecting and evaluating β-cell engagement by GLP-1 receptor agonists by monitoring miR-132 and miR-212 expression in a subject is described. The methods herein are particularly useful in the context of longitudinal clinical trials, such as those designed for testing the durability of any single or combination therapy in type 2 diabetes populations. Because the expression of these miRNAs is not affected by glucose, fatty acid, insulin, or β-cell function, monitoring miR-132 and miR-212 expression can be used to monitor the efficacy of any agent that effects an increase cAMP in β-cells. Such agents include for example, GLP-1, glucagon, GPR-119, and GIP receptor agonists; dipeptidyl peptidase IV (DPP IV) inhibitors; and phosphodiesterase inhibitors.
    • 微小RNA(miRNA)是调节基因表达的短非编码RNA,其在许多细胞类型中起重要作用,包括本文所述的胰腺β细胞。 胰高血糖素样肽-1(GLP-1)是膳食摄入后从肠道L细胞释放的激素,对β细胞功能具有多效性,包括提高细胞内cAMP水平,现在代表了2型糖尿病的重要疗法。 miR-132和miR212的表达由CREB蛋白上调,响应细胞中cAMP水平升高; 因此,描述了通过监测受试者中的miR-132和miR-212表达来检测和评估GLP-1受体激动剂的β细胞接合的方法。 本文的方法在纵向临床试验的背景下特别有用,例如设计用于测试2型糖尿病人群中任何单一或联合疗法的耐久性的那些。 由于这些miRNA的表达不受葡萄糖,脂肪酸,胰岛素或β细胞功能的影响,监测miR-132和miR-212的表达可用于监测影响ß- 细胞。 这些药剂包括例如GLP-1,胰高血糖素,GPR-119和GIP受体激动剂; 二肽基肽酶IV(DPP IV)抑制剂; 和磷酸二酯酶抑制剂。